Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer

Abstract

Objective: MicroRNAs (miRNAs) have been found to play important roles in the development of non-small cell lung carcinoma (NSCLC). The aim of this study was to analyze the expression and clinical value of serum miR-185 in NSCLC. Methods: Serum miR-185 levels were detected in 146 NSCLC patients, 50 patients with carcinoma in situ, 25 patients with non-malignant lung diseases (NMLD), and 80 healthy controls using quantitative reverse transcription PCR. The correlation between serum miR-185 level and clinical status of NSCLC was explored. Results: The results revealed that serum miR-185 expression was progressively decreased in healthy controls, patients with NMLD, patients with carcinoma in situ and NSCLC patients. In addition, compared to carcinoembryonic antigen (CEA), serum miR-185 demonstrated better diagnostic accuracy for discriminating patients with carcinoma from healthy controls, NSCLC patients from healthy controls and NSCLC patients from patients with carcinoma in situ. In addition, serum miR-185 levels were significantly elevated in post-treated samples compared to the pre-treated samples. Moreover, reduced serum miR-185 was closely associated with unfavorable clinicopathological parameters and worse survival. Univariate and multivariate cox regression analysis confirmed that serum miR-185 was an independent prognostic indicator for NSCLC. Conclusions: Collectively, our findings have demonstrated that serum miR-185 might serve as a promising and robust biomarker for the early detection and prognosis prediction of NSCLC.

New biochemical, immune and molecular markers in lung cancer: Diagnostic and prognostic opportunities

“…158 Others reported an association between miR-153, 159 miR-494, 160 miR-519d 161 and more advanced clinical stage, presence of lymph node metastases, and worse OS in NSCLC patients. Similar results regarding a poor prognosis in NSCLC patients were reported for the downregulation of miR-184, 162 miR-185, 163 miR-770, 164 and miR-30a-5p, 165 , and the upregulation of miR-23b-3p, miR-10b-5p and miR-21-5p, 166 miR-31, 167 miR-378, 168 miR-942, and miR-601. 169 On the contrary, a high expression of miR-3195 resulted in longer OS, 170 while miR-21 and miR-4257 were established as predictors of NSCLC recurrence.…”

Dysregulated circulating miR-4429 serves as a novel non-invasive biomarker and is correlated with EGFR mutation in patients with non-small cell lung cancer

“…A study by Sun et al has shown that serum miR30a-5p may function as a new biomarker for the diagnosis and prognosis of colorectal cancer [ 26 ]. Serum miR-185 [ 27 ] and serum miR1246 [ 28 ] have been found to be used as diagnostic and prognostic biomarkers for NSCLC.…”

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients

“…The role of miR-185 in oral cancer (131), prostate cancer (132) and in NSCLC has been previously evaluated (133,134). In 2020, Liu et al (68) demonstrated that serum miR-185 might be a promising biomarker for NSCLC early detection. Their work showed significantly reduced miR-185 expression in NSCLC patients with lymph node metastasis at the advanced stage or with poor differentiation.…”

“…Significantly, miR-518b over-expression was likewise associated with shorter survival of patients (p = 0.009). J. Liu et al (68) as first demonstrated that decreased level of serum miR-185 was markedly associated with worse survival and adverse clinicopathological parameters in NSCLC patients. Performing univariate and multivariate Cox regression analysis indicated that this miRNA was an independent prognostic indicator for NSCLC.…”